
Opinion|Videos|June 9, 2025
Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).
Advertisement
Future Directions
- Key Discussion Points:
- Dr Lovly highlighted promising clinical trials that may reshape ALK+ NSCLC treatment sequencing strategies
Notable Expert Insights
- Dr Dietrich provided critical analysis of the CROWN trial data and the implications of matching-adjusted indirect comparisons between different ALK inhibitors for clinical decision-making
- Dr Lovly offered specialized perspective on resistance patterns and mutation-guided therapy selection, particularly incorporating emerging data on investigational agents like NVL-655
- Elizabeth Castronovo contributed valuable real-world experience comparing clinical trial outcomes with observed patient responses and toxicity management approaches
- Mary Grizzard emphasized patient-centered care considerations, highlighting education strategies and practical challenges faced during treatment transitions
The panelists collectively addressed the evolving treatment landscape for ALK+ NSCLC, emphasizing evidence-based approaches to optimize patient outcomes through appropriate therapy selection, sequencing strategies, and adverse event management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Major Bleeding Prevention, Treatment Requires Vigilance in Patients With ET
2
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
3
Medicare Insulin Savings Model Cuts Costs, Boosts Access, Report Finds
4
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
5